ACONSELHAMENTO GENÉTICO NO CÂNCER GINECOLÓGICO HEREDITÁRIO
DOI:
https://doi.org/10.61229/mpj.v1i1.7Palabras clave:
Câncer ginecológico, aconselhamento genético, testes genéticosResumen
O câncer epitelial de ovário e o câncer de endométrio apresentam uma alta taxa de mortalidade entre mulheres de todas as idades. Tanto na avaliação diagnóstica quanto de risco para essas neoplasias malignas deve-se considerar a possibilidade de uma etiologia hereditária, a qual pode ser identificável através de testes genéticos. O câncer de ovário de origem epitelial é um dos cânceres com maior relação com a hereditariedade, até 25% dos casos apresentam mutações germinativas identificáveis. Síndromes e/ou genes de alto risco para o câncer ginecológico como a Síndrome de predisposição ao câncer de mama e ovários associadas aos genes BRCA1/2, síndrome de Lynch aos genes MMR, Síndrome de Cowden ao gene PTEN, devem ser reconhecidas e podem ter impacto relevante para guiar condutas cirúrgicas e oncológicas. Entretanto, a abordagem faz-se através do processo do aconselhamento genético que é um processo dinâmico e que pode ser decisivo na avaliação do paciente oncológico e familiares em risco para câncer.
Descargas
Citas
Ngeow J, Eng C. Precision medicine in heritable cancer: when somatic tumour testing and germline mutations meet. NPJ Genom Med,2016;37:1:15006. https://doi.org/10.1038/npjgenmed.2015.6. DOI: https://doi.org/10.1038/npjgenmed.2015.6
Observatório Global do Câncer (iarc.fr). Disponível em >http://gco.iarc.fr<. Acesso em 26/12/2021
Paulino E, de Melo AC, Silva-Filho AL et al. Panorama of Gynecologic Cancer in Brazil. JCO Glob Oncol, 2020;6:1617-1630. DOI: https://doi.org/10.1200/GO.20.00099
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin, 2020;70:7-30. https://doi.org/10.3322/caac.21590. DOI: https://doi.org/10.3322/caac.21590
Henderson JT, Webber EM, Sawaya GF. Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018;319(6):595-606. DOI: https://doi.org/10.1001/jama.2017.21421
Buys SS, Sandbach JF, Gammon A et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017;123(10):1721-1730. https://doi.org/10.1002/cncr.30498. DOI: https://doi.org/10.1002/cncr.30498
National Cancer Comprehensive Network Clinical Practice Guidelines in Oncology: genetic/familial high risk assessment: colorectal. Version 1.2022. NCCN Guidelines for Genetic/Familial High-Risk Assessment.Diponível em: Guidelines Detail (nccn.org) - Acesso em dezembro de 2022.
Liu YL, Breen K, Catchings A, et al. Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes. JCO Oncol Pract,2021;28. https://doi.org/10.1200/OP.21.00382. DOI: https://doi.org/10.1200/OP.21.00382
Balmaña J, Digiovanni L, Gaddam P, et al. Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. J Clin Oncol, 2016;34:4071-4078. https://doi.or/10.1200/JCO.2016.68.4316. DOI: https://doi.org/10.1200/JCO.2016.68.4316
Stratton JF et al. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol,1998;105:493-9. https://doi.or/10.1111/j.1471-0528.1998.tb10148.x. DOI: https://doi.org/10.1111/j.1471-0528.1998.tb10148.x
Manchanda R et al. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis. J Med Genet,2016;53:591-9. https://doi.or/10.1136/jmedgenet-2016-103800. DOI: https://doi.org/10.1136/jmedgenet-2016-103800
Dörk T et al. Genetic Susceptibility to Endometrial Cancer: Risk Factors and Clinical Management. Cancers (Basel),2020;25:12-2407. https://doi.org/10.3390/cancers12092407. DOI: https://doi.org/10.3390/cancers12092407
Haraldsdottir S, Rafnar T, Frankel WL, et al. Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. Nat Commun,2017;8:14755. https://doi.org/10.1038/ncomms14755. DOI: https://doi.org/10.1038/ncomms14755
Yehia L and Charis Eng. PTEN Hamartoma Tumor Syndrome. G. PTEN Hamartoma Tumor Syndrome - GeneReviews® - NCBI Bookshelf (nih.gov). Acesso em 28/02/2022.
Coyne GO’S et al. PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components. Oncotarget. 2022;165-180. https://doi.org/10.2147/OTT.S278092 DOI: https://doi.org/10.2147/OTT.S278092
WilsonIII DM, Deacon AM, Duncton MAJ et al. Fragment- and structure-based drug discovery for developing therapeutic agents targeting the DNA Damage Response. Prog Biophys Mol Biol, 2021;163:130-142. https://doi.org/10.1016/j.pbiomolbio.2020.10.005 DOI: https://doi.org/10.1016/j.pbiomolbio.2020.10.005
Jasin M, Rothstein R. Repair of Strand Breaks by Homologous Recombination. CSHperspect, 2013. https://doi.org/10.1101/cshperspect.a012740. DOI: https://doi.org/10.1101/cshperspect.a012740
Andres SN et al. A human XRCC4-XLF complex bridges DNA. Nucleic Acids Res, 2012;40:1868-78. https://doi.org/10.1093/nar/gks022. DOI: https://doi.org/10.1093/nar/gks022
Yin, C et al. Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition? Cancers 2022;14:2561. https://doi.org/10.3390/cancers14102561. DOI: https://doi.org/10.3390/cancers14102561
Sullivan MR, Bernstein KA. RAD-ical New Insights into RAD51 Regulation. Genes (Basel),2018:9(12):629. https://doi.org/10.3390/genes9120629. DOI: https://doi.org/10.3390/genes9120629
Martino J, Bernstein KA. The Shu complex is a conserved regulator of homologous recombination. FEMS Yeast Research,2016:16. https://doi.org/10.1093/femsyr/fow073. DOI: https://doi.org/10.1093/femsyr/fow073
Arnoult N, Correia A, Ma J et al. Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN. Nature, 2017;549(7673):548-552. https://doi.org/10.1038/nature24023. DOI: https://doi.org/10.1038/nature24023
Kobayashi H et al. Hereditary breast and ovarian cancer susceptibility genes (Review). Oncol Rep,2013;30:1019-1029. https://doi.org/10.3892/or.2013.2541. DOI: https://doi.org/10.3892/or.2013.2541
Harter P, Mouret-Reynier MA, Pignata S et al. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Gynecol Oncol, 2022;164:254-264. https://doi.org/10.1016/j.ygyno.2021.12.016. DOI: https://doi.org/10.1016/j.ygyno.2021.12.016
Tutt ANJ, Garber JE, Kaufman B et al. Adjuvant Olaparib for Patients with BRCA1 or BRCA2 Mutated Breast Cancer. N Engl J Med, 2021;384:2394-2405. http://dx.doi.org/10.1056/NEJMoa2105215. DOI: https://doi.org/10.1056/NEJMoa2105215
Palmero EI, Carraro DM, Alemar B, et al. The germline mutational landscape of BRCA1 and BRCA2 in Brazil. Sci Rep, 2018;8:1–10. DOI: https://doi.org/10.1038/s41598-018-27315-2
Oliveira ES, Soares BL, Lemos S, et al. Screening of the BRCA1 gene in Brazilian patients with breast and/or ovarian cancer via high-resolution melting reaction analysis. Fam Cancer, 2016;15(2):173–81. DOI: https://doi.org/10.1007/s10689-015-9858-0
Cipriano NM, de Brito AM, de Oliveira ES et al. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil. Breast Cancer,2019:26:397–405. http://dx.doi.org/10.1007/s12282-018-00938-z. DOI: https://doi.org/10.1007/s12282-018-00938-z
Guindalini RSC, Viana DV, Kitajima JPFW et al. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. Sci Rep, 2022;12:4190. http://dx.doi.org/10.1038/s41598-022-07383-1. DOI: https://doi.org/10.1038/s41598-022-07383-1
Brasil. Agência Nacional de Saúde Suplementar - ANS. Rol de Procedimentos e Eventos em Saúde 2021 - Anexo II Diretrizes de utilização para cobertura de procedimentos na saúde suplementar. Resolução Normativa - RN no 456/2021.
Projeto de Lei obriga SUS a cobrir exame dos genes BRCA1 e BRCA 2 - Instituto Oncoguia. Disponível em: http://www.oncoguia.org.br. Acesso em 15 de Outubro de 2022.
Patch C, Middleton A. Genetic counseling in the era of genomic medicine. Br Med Bull, 2018;126:27-36. DOI: https://doi.org/10.1093/bmb/ldy008
Davies SC. Annual Report of the Chief Medical Officer 2016, Generation Genome. London: Department of Health; 2017.
Henson JW, Resta RG. Genetic Counseling Considerations. In: Diagnosis and management of hereditary cancer. 1st edn. London:Elsevier;2021. p. 40-41.
Richards S, Aziz N, Bale S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med,2015;17:405423. https://doi.org/10.1038/gim.2015.30. DOI: https://doi.org/10.1038/gim.2015.30
Henson JW, Resta RG. ACMG Evidence of pethogenicity. In: Diagnosis and management of hereditary cancer. 1st edn. London: Elsevier;2021, p. 68-69. DOI: https://doi.org/10.1016/B978-0-323-90029-4.00009-2
Pepin MG, Murray ML, Bailey S, et al. The challenge of comprehensive and consistent sequence variant interpretation between clinical laboratories. Genet Med. 2016;18(1):20-4. https://doi.org/10.1038/gim.2015.31. DOI: https://doi.org/10.1038/gim.2015.31
Harrison SM, Dolinsky JS, Knight Johnson AE, et al. Clinical laboratories collaborate to resolve differences in variant interpretations submitted to ClinVar. Genet Med,2017;19:1096-1104. https://doi.org/10.1038/gim.2017.14. DOI: https://doi.org/10.1038/gim.2017.14
Schrader KA, Cheng DT, Joseph V et al. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncol, 2016;2:104-11. https://doi.org/10.1001/jamaoncol.2015.5208. DOI: https://doi.org/10.1001/jamaoncol.2015.5208
Konstantinopoulos PA, Norquist B, Lacchetti C, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol, 2020;38:1222-1245. https://doi.org/10.1200/JCO.19.02960. DOI: https://doi.org/10.1200/JCO.19.02960
Randall LM, Pothuri B. The Genetic Prediction of Risk for Gynecologic Cancer. Gynecol Oncol,2016;141:10-6. https://doi.org/10.1016/j.ygyno.2016.03.007. DOI: https://doi.org/10.1016/j.ygyno.2016.03.007
Yurgelun MB, Hampel H. Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention. Am Soc Clin Oncol Educ Book, 2018;38:101-109. https://doi.org/10.1200/EDBK_208341. DOI: https://doi.org/10.1200/EDBK_208341
Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med, 2015;372:2243-57. https://doi.or/10.1056/NEJMsr1501341. DOI: https://doi.org/10.1056/NEJMsr1501341
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Mário Penna Journal
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Autores que publicam nesta revista concordam com os seguintes termos:
- Declaro que o presente artigo é original, não tendo sido submetido à publicação em qualquer outro periódico nacional ou internacional, quer seja em parte ou em sua totalidade.
- Declaro, ainda, que uma vez publicado na revista Mário Penna Journal, editada pelo Instituto Mário Penna, o mesmo jamais será submetido por mim ou por qualquer um dos demais co-autores, caso haja, a qualquer outro periódico.
- Por meio deste instrumento, em meu nome e em nome dos demais co-autores, porventura existentes, cedo os direitos autorais do referido artigo ao Instituto Mário Penna e declaro estar ciente de que a não observância deste compromisso submeterá o infrator a sanções e penas previstas na Lei de Proteção de Direitos Autorias (Nº9609, de 19/02/98).
A Revista Mário Penna Journal é licenciada sob uma licença Creative Commons Atribuição-NãoComercial-CompartilhaIgual 4.0 Internacional
